10X Genomics Inc (Class A)

20 Aug 2026, 23:16 UTC

10X Genomics Inc. shares traded lower after-market, amid broader market pressure from rising bond yields and concerns over high borrowing costs and geopolitical risks.

19 Aug 2026, 23:06 UTC

10X Genomics Inc shares are higher in after-market trading, reflecting strong momentum above the 20-day moving average and near the top of its one-month range.

18 Aug 2026, 23:31 UTC

10X Genomics Inc shares are higher in after-market trading, maintaining a notable increase while staying above the 20-day moving average. No specific news was identified.

17 Aug 2026, 19:16 UTC

10X Genomics Inc shares are higher today, recovering from an initial dip. The stock remains above its 20-day moving average amid mixed economic indicators.

14 Aug 2026, 20:06 UTC

10X Genomics Inc shares are lower today amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13 Aug 2026, 19:16 UTC

10X Genomics Inc reported Q2 revenue of $151 million, exceeding estimates. Shares are higher as management raises full-year revenue guidance to $620 million.

12 Aug 2026, 19:46 UTC

10X Genomics Inc. shares are lower today, having retraced from an early peak. The stock remains above its 20-day moving average.

11 Aug 2026, 20:06 UTC

10X Genomics Inc. shares are lower today amid routine trading, despite earlier fluctuations and remaining above the 20-day moving average.

10 Aug 2026, 20:03 UTC

10X Genomics shares rise as Piper Sandler and Canaccord Genuity raise price targets to $47.00 and $60.00, respectively, amid increased trading volume.

7 Aug 2026, 23:16 UTC

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

6 Aug 2026, 23:02 UTC

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5 Aug 2026, 19:26 UTC

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3 Aug 2026, 19:36 UTC

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31 Jul 2026, 19:36 UTC

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30 Jul 2026, 17:06 UTC

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29 Jul 2026, 19:27 UTC

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28 Jul 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27 Jul 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24 Jul 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 Jul 2026, 23:26 UTC

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 Jul 2026, 19:51 UTC

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 Jul 2026, 19:53 UTC

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 Jul 2026, 19:16 UTC

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.